CASSAVA SCIENCES INC (SAVA) Stock Price, Quote, News and Overview
NASDAQ:SAVA - Nasdaq - US14817C1071 - Common Stock - Currency: USD
SAVA Quote, Performance and Key Statistics
1.66
0 (0%)
The current stock price of SAVA is 1.66 USD. In the past month the price decreased by -5.14%. In the past year, price decreased by -92.57%.
SAVA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 66.13 | 815.02B | ||
| JNJ | JOHNSON & JOHNSON | 15.42 | 373.36B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.05 | 278.02B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14 | 219.57B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.63B | ||
| MRK | MERCK & CO. INC. | 10.45 | 200.91B | ||
| SNY | SANOFI-ADR | 11.95 | 131.07B | ||
| PFE | PFIZER INC | 7.32 | 129.20B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 42.71 | 99.07B | ||
| GSK | GSK PLC-SPON ADR | 8.62 | 75.99B | ||
| ZTS | ZOETIS INC | 25.73 | 67.93B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.15 | 47.56B |
Related stock screener links
About SAVA
Company Profile
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. The company is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.
Company Info
CASSAVA SCIENCES INC
6801 N. Capital of Texas Highway, Building 1
Austin TEXAS 78731 US
CEO: Remi Barbier
Employees: 29
Company Website: https://www.cassavasciences.com/
Investor Relations: http://investor.paintrials.com/
Phone: 15125012444
CASSAVA SCIENCES INC / SAVA FAQ
What is the stock price of CASSAVA SCIENCES INC today?
The current stock price of SAVA is 1.66 USD.
What is the ticker symbol for CASSAVA SCIENCES INC stock?
The exchange symbol of CASSAVA SCIENCES INC is SAVA and it is listed on the Nasdaq exchange.
On which exchange is SAVA stock listed?
SAVA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CASSAVA SCIENCES INC stock?
7 analysts have analysed SAVA and the average price target is 2.04 USD. This implies a price increase of 22.89% is expected in the next year compared to the current price of 1.66. Check the CASSAVA SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CASSAVA SCIENCES INC worth?
CASSAVA SCIENCES INC (SAVA) has a market capitalization of 80.19M USD. This makes SAVA a Micro Cap stock.
How many employees does CASSAVA SCIENCES INC have?
CASSAVA SCIENCES INC (SAVA) currently has 29 employees.
What are the support and resistance levels for CASSAVA SCIENCES INC (SAVA) stock?
CASSAVA SCIENCES INC (SAVA) has a resistance level at 1.67. Check the full technical report for a detailed analysis of SAVA support and resistance levels.
Should I buy CASSAVA SCIENCES INC (SAVA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SAVA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SAVA, evaluating the profitability, health, valuation and growth aspects
- CASSAVA SCIENCES INC (SAVA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CASSAVA SCIENCES INC (SAVA) Sales and EPS estimates to see what analysts future expectations are.
- CASSAVA SCIENCES INC (SAVA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CASSAVA SCIENCES INC (SAVA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CASSAVA SCIENCES INC (SAVA) Stock Chart to make your own analysis
- CASSAVA SCIENCES INC (SAVA) Latest news and press-releases to stay up to date.
Does CASSAVA SCIENCES INC (SAVA) stock pay dividends?
SAVA does not pay a dividend.
When does CASSAVA SCIENCES INC (SAVA) report earnings?
CASSAVA SCIENCES INC (SAVA) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of CASSAVA SCIENCES INC (SAVA)?
CASSAVA SCIENCES INC (SAVA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.45).
What is the Short Interest ratio of CASSAVA SCIENCES INC (SAVA) stock?
The outstanding short interest for CASSAVA SCIENCES INC (SAVA) is 34.25% of its float. Check the ownership tab for more information on the SAVA short interest.
SAVA Technical Analysis
SAVA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SAVA. No worries on liquidiy or solvency for SAVA as it has an excellent financial health rating, but there are worries on the profitability.
SAVA Financial Highlights
Over the last trailing twelve months SAVA reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 37.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.45% | ||
| ROE | -16.71% | ||
| Debt/Equity | 0 |
SAVA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to SAVA. The Buy consensus is the average rating of analysts ratings from 7 analysts.